Cover ImageSALE


rhEPO Market in China 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 361398
出版日期 內容資訊 英文 65 Pages
Back to Top
中國的rhEPO市場:2016∼2020年 rhEPO Market in China 2016-2020
出版日期: 2016年06月03日 內容資訊: 英文 65 Pages



第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 促血紅細胞生長素:概要

  • EPO的臨床性使用
  • EPO的濫用
  • EPO使用的風險

第6章 全球促血紅細胞生長素市場

第7章 國家概要

  • 社會趨勢及景氣
  • 醫療改革
  • 醫療基礎設施

第8章 中國的醫藥品供應商的機會

  • 主要的醫藥品供應商
  • 全球及國內供應商的機會

第9章 中國的生物醫藥品市場

第10章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第11章 各終端用戶市場區隔

  • 醫院
  • 藥局

第12章 各用途市場市場區隔

  • ESRD
  • 癌症
  • HIV
  • 創傷、神經疾病

第13章 中國的藥價與償付

第14章 產品研發線

第15章 推動市場的要素

第16章 促進要素的影響

第17章 市場課題

第18章 促進要素與課題的影響

第19章 市場趨勢

第20章 供應商環境

  • 競爭模式
  • 市場分析:2015年
  • 3S Bio
  • Shanghai Chemo
  • Chengdu Di'ao
  • NCPC Genetech
  • Kyowa Hakko Kirin株式會社
  • Shandong Kexing
  • 其他值得注意的供應商

第21章 附錄

第22章 關於Technavio

Product Code: IRTNTR9557

About the Recombinant Human Erythropoietin (rhEPO) Market in China

Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein responsible for producing erythrocytes in the body. In the fetal stage, this protein is produced in the liver; it is secreted by the kidneys in adulthood. During anemic conditions, the body produces an excess of EPO, maintaining the normal levels of red blood cells (RBC). When the endogenous production of EPO is disturbed because of diseases or the use of medications, the normal RBC levels can be maintained by an external supply of EPO-stimulating agents (ESAs). These agents are similar to the natural EPO in structure and function and are administered as injections. They can be produced by recombinant DNA technology and are used to treat anemia due to kidney diseases, cancer, HIV, injuries, or neural diseases.

Technavio's analysts forecast the recombinant human erythropoietin (rhEPO) market in China to grow at a CAGR of 16.89% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the recombinant human erythropoietin (rhEPO) market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and biosimilars used for the treatment of anemia due to renal diseases, cancer chemotherapy, antiretroviral therapy, and wounds and neural diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on application of rhEPO:

  • End-stage renal disease (ESRD)
  • Cancer
  • Human immunodeficiency virus (HIV)
  • Wounds and neural disease

Technavio's report, Recombinant Human Erythropoietin (rhEPO) Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • 3S Bio
  • Shanghai Chemo
  • Chengdu Di'ao
  • NCPC Genetech
  • Kyowa Hakko Kirin
  • Shandong Kexing

Other Prominent Vendors

  • Ahua Pharmaceutical
  • Biosidus
  • Dragon Pharma
  • Huaxin High Biotechnology
  • Kehua Bio-Engineering
  • LG Life Sciences
  • Shenzhen Sai Bao Er Bio-Pharmaceutical
  • Sihuan
  • Shenyang Sunshine Pharmaceutical
  • Uni-Bio Science Group
  • Wanbang Biochemical Pharmaceuticals

Market driver

  • Increase in chronic kidney disease (CKD) and dialysis patient population
  • For a full, detailed list, view our report

Market challenge

  • Complex manufacturing process
  • For a full, detailed list, view our report

Market trend

  • Exploitation of novel therapeutic areas
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Erythropoietin: An overview

  • Clinical uses of EPO
  • Abusive uses of EPO
  • Risks of EPO use

PART 06: Global erythropoietin market

PART 07: China: Country snapshot

  • Social and economic conditions
  • Healthcare reforms
  • Healthcare infrastructure

PART 08: Opportunities for pharmaceutical vendors in China

  • Major pharmaceutical vendors in China
  • Opportunities for global and local vendors

PART 09: Biopharmaceutical market in China

  • Biosimilar market in China
  • Market size and forecast

PART 10: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 11: Market segmentation by end-user

  • Hospitals
  • Retail pharmacies

PART 12: Market segmentation by application

  • ESRD
  • Cancer
  • HIV
  • Wounds and neural disease

PART 13: Drug pricing and reimbursement in China

  • Market-driven drug pricing strategy
  • Scrutinization of illegal pricing of drugs

PART 14: Pipeline portfolio

  • NuPIAO
  • Uni-EPO-Fc

PART 15: Market drivers

  • Increase in CKD and dialysis patient population
  • Growth in prevalence of cancer
  • Support for local manufacturers

PART 16: Impact of drivers

PART 17: Market challenges

  • Complex regulatory framework and approval process
  • Complex manufacturing process
  • Development of alternative therapies

PART 18: Impact of drivers and challenges

PART 19: Market trends

  • Penetration of rhEPO drugs in grade I and II hospitals
  • Exploitation of novel therapeutic areas
  • Initiation of R&D activities by local/domestic vendors

PART 20: Vendor landscape

  • Competitive scenario
  • Market analysis 2015
  • 3S Bio
  • Shanghai Chemo
  • Chengdu Di'ao
  • NCPC Genetech
  • Kyowa Hakko Kirin
  • Shandong Kexing
  • Other prominent vendors

PART 21: Appendix

  • List of abbreviations

PART 22: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Historical timeline of EPO development
  • Exhibit 03: Globally approved EPO biosimilars
  • Exhibit 04: China GDP 2010-2014 ($ trillions)
  • Exhibit 05: China: Healthcare expenditure 2009-2013 (% of GDP)
  • Exhibit 06: Healthcare reforms in China
  • Exhibit 07: China pharmaceutical market overview: SWOT analysis
  • Exhibit 08: New drug approval (NDA) review process in China
  • Exhibit 09: New drug approval process in China
  • Exhibit 10: Drug registration classification and requirements in China
  • Exhibit 11: Notable achievements in biopharmaceutical industry in china
  • Exhibit 12: Biopharmaceutical market in China 2015-2020 ($ billions)
  • Exhibit 13: rhEPO market in China in global biopharmaceutical market 2015
  • Exhibit 14: rhEPO market in China 2015-2020 ($ millions)
  • Exhibit 15: Five forces analysis
  • Exhibit 16: rhEPO market in China by distribution channels 2015
  • Exhibit 17: Share of domestic rhEPO drugs in hospitals in China 2015
  • Exhibit 18: Changes in the drug pricing system before and after 2015 reforms
  • Exhibit 19: Pipeline portfolio: rhEPO market in China
  • Exhibit 20: Impact of drivers
  • Exhibit 21: Impact of drivers and challenges
  • Exhibit 22:S Bio: YoY revenue comparison of EPIAO 2014-2015 ($ millions)
  • Exhibit 23:SBio: Key takeaways
  • Exhibit 24: Shanghai Fosun: YoY revenue and growth rate of blood system products 2013-2015 ($ millions)
  • Exhibit 25: Shanghai Chemo: Key takeaways
  • Exhibit 26: Chengdu Di'ao: Key takeaways
  • Exhibit 27: NCPC Genetech Biotechnology: Key takeaways
  • Exhibit 28: Kyowa Hakko Kirin: Key takeaways
  • Exhibit 29: Shandong Kexing: Key takeaways
Back to Top